Physician profile
Jonathan L Smith
NPI 1346717295
$3,787.57
in general payments reported to CMS, 2019-2025
27 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $817 · 2022: $1,706 · 2023: $546 · 2024: $363 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,156.97 | 2022-2023 | Ha Minuteman G3-R |
| Abbvie INC. | $644.20 | 2022-2025 | |
| Amgen INC. | $358.82 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.26 | 2021-2023 | Relistor |
| Pacira Therapeutics, INC. | $152.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.80 | 2022 | |
| Lilly USA, LLC | $118.26 | 2021-2023 | Mounjaro |
| Pfizer INC. | $104.24 | 2021-2023 | |
| Braeburn INC. | $97.64 | 2024-2025 | Brixadi |
| Grt US Holding, INC. | $96.38 | 2021 | |
| Grifols USA, LLC | $88.64 | 2023-2024 | Prolastin-C Liquid |
| Lundbeck LLC | $71.35 | 2021-2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $68.54 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.40 | 2023-2025 | Caplyta |
| Tersera Therapeutics LLC | $49.31 | 2021-2023 | Prialt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $40.84 | 2025 | Rexulti |
| Ibsa Pharma INC. | $39.53 | 2021 | |
| Vanda Pharmaceuticals INC. | $33.43 | 2025 | Hetlioz, Fanapt |
| Scilex Pharmaceuticals INC. | $31.45 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $26.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.17 | 2022 | |
| Stimwave Technologies Incorporated | $24.05 | 2021 | |
| Medtronic, INC. | $21.69 | 2023 | Intellis Adaptivestim |
| Pacira Pharmaceuticals Incorporated | $16.63 | 2022 | |
| Indivior INC. | $14.35 | 2025 | Sublocade |
| Allergan, INC. | $13.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.32 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.